No Data
TOT BIOPHARM-B (01875.HK) plans to hold a Board of Directors meeting on March 11 to approve the annual performance.
Gelonghui reported on February 27 that TOT BIOPHARM-B (01875.HK) announced that a Board of Directors meeting will be held on March 11, 2025 (Tuesday) to consider and approve the group's full-year performance for the year ending December 31, 2024, as well as to address Other matters.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Dongyao Pharmaceutical - B (01875) revenue in the first three quarters increased by 49% year-on-year to 0.809 billion yuan.
Dongyao Pharmaceuticals - B (01875) announced that as of the nine months ended September 30, 2024, the Group's revenue...